Edesa Biotech, Inc.

For the period ended Sep 30, 2025. Filed Dec 12, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Dec 12, 2025

EDSA$2.02-18.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at September 30, 2025 and 2024

	September 30, 2025	September 30, 2024
Assets:
Current assets:
Cash and cash equivalents	$10,792,172	$1,037,320
Accounts and other receivable	642,866	270,908
Prepaid expenses and other current assets	77,838	367,394
Total current assets	11,512,876	1,675,622
Non-current assets:
Long-term deposits	39,966	41,151
Intangible asset, net	1,977,676	2,078,848
Right-of-use assets	-	18,361
Total assets	$13,530,518	$3,813,982
Liabilities and shareholders' equity:
Current liabilities:
Accounts payable and accrued liabilities	$1,078,536	$1,812,960
Short-term right-of-use lease liabilities	-	19,867
Total current liabilities	1,078,536	1,832,827
Shareholders' equity:
Capital shares
Authorized unlimited common shares without par value
Issued and outstanding:
7,141,783 common shares (September 30, 2024 - 3,247,389)	54,515,421	47,236,024
Authorized preferred shares issued and outstanding
150 Series A-1 preferred shares (September 30, 2024 - 0)	1,092,133	-
834 Series B-1 preferred shares (September 30, 2024 - 0)	8,168,063	-
Additional paid-in capital	14,753,110	13,576,757
Accumulated other comprehensive loss	(165,771)	(242,613)
Accumulated deficit	(65,910,974)	(58,589,013)
Total shareholders' equity	12,451,982	1,981,155
Total liabilities and shareholders' equity	$13,530,518	$3,813,982

**Consolidated Statements of Operations and Comprehensive Loss

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.